Key facts
- Olatec Therapeutics’s last known valuation is $230.0M (Jul 2025).
- It has raised $118.8M; the latest was Later Stage VC ($14.4M) in Jul 2025.
- Notable investors include Advection Growth Capital, Kenneth Wells, Milano Investment Partners, Peter Gonzalez, Sanders Morris.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Olatec Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Olatec Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Olatec Therapeutics
Operator of a biopharmaceutical company intended to develop novel, safe, oral, small-molecule therapeutics that target the NLRP3(nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome and Interleukin-1 pathways. The company's portfolio includes a proprietary pipeline of potent and selective NLRP3 inflammasome inhibitors used to reduce pro-inflammatory cytokines, which are known to play a key role in chronic inflammation, enabling medical practitioners to treat a breadth of acute and chronic inflammatory and immune-related diseases, including arthritis, cancer, cardio-metabolic and neuroinflammatory diseases.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2003
- Employees
- 8
- Website
- olatec.com/
- Ownership
- Privately Held (backing)
Olatec Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Olatec Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Olatec Therapeutics in its N-PORT filings yet. We sweep new filings monthly.